Breast (Edinburgh, Scotland) · 2026
Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uyar Galip Can, Başkurt Kadriye, Oruç Ahmet, Majidova Nargiz, Akdoğan Orhun, Yeşilbaş Enes, Bir Yücel Kadriye, Karakurt Eryılmaz Melek, Sütcüoğlu Osman, Çakmak Öksüzoğlu Ömür Berna, Altınbaş Mustafa
Аннотация
BACKGROUND: Pathological complete response (pCR) after neoadjuvant therapy (NAT) is associated with long-term outcomes in breast cancer (BC). The remnant cholesterol inflammatory index (RCII) integrates lipid-related and inflammatory components, but its role in pCR prediction remains unclear.
METHODS: This multicenter retrospective study included women with invasive BC treated with NAT between January 2022 and January 2026. Prespecified multivariable logistic regression models incorporating baseline inflammatory, metabolic, and clinicopathologic variables were developed in a training cohort and evaluated in an independent external validation cohort without recalibration. Model performance was assessed using discrimination and calibration metrics.
RESULTS: Among 422 patients, 157 (37.2%) achieved pCR. In the clinically adjusted model, triple-negative BC (OR 7.56, 95% CI 2.74-20.86), HER2-positive BC (OR 4.13, 95% CI 2.15-7.92), and lower log-RCII (OR 0.48, 95% CI 0.33-0.69) were independently associated with pCR. External validation yielded an AUC of 0.84 (95% CI 0.76-0.91). The calibration slope was 0.94, while the calibration intercept of -0.60 indicated systematic overprediction of pCR probability. Sensitivity and internal validation analyses supported the robustness of the primary findings.
CONCLUSION: Log-RCII was independently associated with pCR and provided incremental predictive information beyond standard clinicopathologic factors. The model showed favorable discrimination in the external validation cohort, but systematic overprediction indicates that further prospective validation and potential recalibration are warranted before clinical implementation.
METHODS: This multicenter retrospective study included women with invasive BC treated with NAT between January 2022 and January 2026. Prespecified multivariable logistic regression models incorporating baseline inflammatory, metabolic, and clinicopathologic variables were developed in a training cohort and evaluated in an independent external validation cohort without recalibration. Model performance was assessed using discrimination and calibration metrics.
RESULTS: Among 422 patients, 157 (37.2%) achieved pCR. In the clinically adjusted model, triple-negative BC (OR 7.56, 95% CI 2.74-20.86), HER2-positive BC (OR 4.13, 95% CI 2.15-7.92), and lower log-RCII (OR 0.48, 95% CI 0.33-0.69) were independently associated with pCR. External validation yielded an AUC of 0.84 (95% CI 0.76-0.91). The calibration slope was 0.94, while the calibration intercept of -0.60 indicated systematic overprediction of pCR probability. Sensitivity and internal validation analyses supported the robustness of the primary findings.
CONCLUSION: Log-RCII was independently associated with pCR and provided incremental predictive information beyond standard clinicopathologic factors. The model showed favorable discrimination in the external validation cohort, but systematic overprediction indicates that further prospective validation and potential recalibration are warranted before clinical implementation.